Giuseppe Di Grazia, Research Fellow at Institut d’Investigacions Biomèdiques August Pi i Sunyer, shared a post on LinkedIn about a recent paper he co-authored with colleagues published in npj Breast Cancer:
“We’re thrilled to share our latest perspective article published in npj Breast Cancer: ‘Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology.’
In this work, we explore how dynamic biomarkers, from tissue/liquid biopsies to metabolic imaging, can redefine therapeutic selection and monitoring in HR+/HER2- breast cancer, tackling resistance and paving the way for true precision oncology.
Our goal is to outline a practical path for integrating these tools into clinical trials and practice, making treatment decisions increasingly personalized and grounded in real-time tumor biology.
We’d love to hear your thoughts on the role of dynamic biomarkers in the future of HR+/HER2- breast cancer treatment!
A great thanks to all my co-authors!”
Title: Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology
Authors: Giuseppe Di Grazia, Rodrigo Sánchez-Bayona, Climent Casals-Pascual, Tomás Pascual, Daniele Generali, Alessandra Gennari, Paolo Vigneri, Nadia Harbeck, Javier Cortés, Aleix Prat, Francesco Schettini
Read the Full Article.
More posts featuring Giuseppe Di Grazia.